Table 1. Clinical and therapeutic features of patients initially treated with MTX chemotherapy.
| Control group n=489 | Study group n=166 | P-value | |
|---|---|---|---|
| Maternal age (years) | |||
| Median (range) | 30 (18–46) | 31 (21–45) | NSa |
| Start MTX (weeks after evacuation) | |||
| Median (range) | 10 (4–27) | 7 (3–31) | <0.0001a |
| Prechemotherapy hCG (IU l−1) | |||
| Median (range) | 4614 (50–5.8*104) | 23667 (638–1.8*105) | <0.0001a |
| Number of courses MTX | |||
| Median (range) | 6 (3–10) | 4 (2–6) | <0.0001a |
| Number of courses actinomycin D | |||
| Median (range) | 5 (1–7) | 2 (1–5) | NA |
| Number of courses EMA/CO | |||
| Median (range) | NA | 5 (2–11) | NA |
EMA/CO=etoposide, MTX, actinomycin D, cyclophosphamide, oncovin; hCG=human chorionic gonadotropin; MTX=methotrexate; NS=not significant; NA=not applicable.
Range=5th to 95th percentile.
a
Mann–Whitney U-test.